Several economic benefits stem from engaging in care soon after HIV transmission and maintaining viral load suppression, noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor, Midwestern University College of Pharmacy.
Less hospitalization, health care dollars spent, and missed days of work, as well as better outcomes, especially for patients engaged in care soon after transmission, are all economic benefits from maintaining viral load suppression when living with HIV, noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University College of Pharmacy who practices at Northwestern Medicine's Infectious Disease Center in Chicago.
Transcript
What are the economic benefits of maintaining viral load suppression?
There's a lot of literature confirming that patients with an undetectable viral load have less hospitalizations and better outcomes than patients with a detectable viral load. And patients that get into care early after transmission, so if we can diagnose them early in the disease course, they also spend less health care dollars overall, both indirect and directly.
Direct benefits to the patient with having that stronger immune system, they’re potentially going to the doctor less often, they're having less issues, no opportunistic infections. And then indirectly over the patient's lifetime, if they're feeling better and have a better immune system, they have less missed days of work.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
2 Commerce Drive
Cranbury, NJ 08512